T. Rowe Price Associates’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-114,265
| Closed | -$2.19M | – | 2884 |
|
|
2020
Q4 | $2.19M | Sell |
114,265
-345,894
| -75% | -$6.64M | ﹤0.01% | 1602 |
|
|
2020
Q3 | $6.18M | Sell |
460,159
-568,979
| -55% | -$7.64M | ﹤0.01% | 1377 |
|
|
2020
Q2 | $43.6M | Sell |
1,029,138
-42,079
| -4% | -$1.78M | 0.01% | 892 |
|
|
2020
Q1 | $29.6M | Sell |
1,071,217
-2,764
| -0.3% | -$76.3K | ﹤0.01% | 944 |
|
|
2019
Q4 | $34.9M | Buy |
1,073,981
+7,661
| +0.7% | +$249K | ﹤0.01% | 1024 |
|
|
2019
Q3 | $27.8M | Buy |
1,066,320
+23,874
| +2% | +$621K | ﹤0.01% | 1049 |
|
|
2019
Q2 | $38.2M | Buy |
1,042,446
+672,721
| +182% | +$24.7M | 0.01% | 978 |
|
|
2019
Q1 | $8.18M | Buy |
369,725
+100
| +0% | +$2.21K | ﹤0.01% | 1345 |
|
|
2018
Q4 | $5.2M | Buy |
369,625
+118,954
| +47% | +$1.67M | ﹤0.01% | 1397 |
|
|
2018
Q3 | $4.87M | Buy |
+250,671
| New | +$4.87M | ﹤0.01% | 1459 |
|